NuElectric moves forward on patent for pathogen-identifying technology
A NuElectric subsidiary is moving forward with a patent application for a technology that extracts and identifies Cryptosporidium and Giardia, two waterborne parasites that can cause serious gastrointestinal problems.
TARPON SPRINGS, Fla., March 28, 2001 — A NuElectric subsidiary is moving forward with a patent application for a technology that extracts and identifies Cryptosporidium and Giardia, two waterborne parasites that can cause serious gastrointestinal problems.
NuElectric's subsidiary, Zorax, Inc., owns the license for the technology developed at Johns Hopkins University.
"Our due diligence always proved to be positive regarding the Zorax technology. Our decision to proceed on securing a patent for the Zorax technology was based on our commitment to increase value for all NuElectric shareholders," stated NuElectric President Laurie C. Scala.
Cryptosporidium and Giardia are commonly occurring parasites in drinking water that can cause serious gastrointestinal symptoms. This technology was invented by C.J. Shiff and T.K. Graczyk and is owned by Johns Hopkins University.
Analysts, stockbrokers, mutual funds, money managers, institutions or individuals seeking additional information can view a recent profile of "NRGE" by the "Conservative Speculator" at
NuElectric identifies, acquires, develops, and markets emerging technologies that conserve energy and protect and enhance the world's natural resources.
The company has also acquired the worldwide exclusive license to an exciting new technology capable of removing arsenic from water. According to a coalition of environmentalists using research from the Environmental Protection Agency (EPA), at least 34 million Americans drink tap water that contains unacceptable levels of arsenic.
SOURCE NuElectric Corporation